Teledyne Technologies' Q2 adj EPS beats estimates, raises FY outlook

Teledyne Technologies Incorporated

22/07/2026 12:06

    

    Overview
  
U.S. industrial technology firm's Q2 revenue rose 9.8%, beating analyst expectations
Adjusted EPS for Q2 increased 20.8%, beating analyst expectations
Company raised full-year 2026 earnings outlook

    

    Outlook
  
Teledyne raises full-year 2026 GAAP EPS outlook to $20.73-$20.99 from $20.08-$20.44
Company raises full-year 2026 non-GAAP EPS outlook to $24.45-$24.65 from $23.85-$24.15

    

    Result Drivers
  
DIGITAL IMAGING GROWTH - Co said organic growth was strongest in Digital Imaging, with higher sales of infrared detectors and systems for space, airborne, and marine unmanned systems, as well as counter unmanned applications
FAVORABLE PRODUCT MIX AND TARIFF REFUNDS - Higher operating income reflected increased net sales, favorable product mix, and tariff refunds, partly offset by higher R&D expense and inventory reserves

    
Company press release: ID:nBw5m39j0a

    

    Key Details
  

            Metric
          

            Beat/Miss
          

            Actual
          

            Consensus Estimate
          
Q2 Sales
Beat
$1.66 bln
$1.58 bln (10 Analysts)
Q2 Adjusted EPS
Beat
$6.28
$5.80 (10 Analysts)
Q2 EPS
 
$5.37
 

    

    Analyst Coverage
  
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the electronic equipment & parts peer group is "buy"
Wall Street's median 12-month price target for Teledyne Technologies Inc is $750.00, about 15.8% above its July 21 closing price of $647.48
The stock recently traded at 26 times the next 12-month earnings vs. a P/E of 25 three months ago

    

    Reuters Recommended Reads
  
July 21 - Northrop Grumman raises 2026 forecasts on strong weapons demand
July 21 - 3M boosts annual profit forecast driven by resilient industrial unit
July 21 - Danaher Q2 revenue, adjusted EPS beats on life sciences segment strength; raises outlook

    
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)